CDx Diagnostics Founder and CSO Shares Company ’s Journey

CDx Diagnostics is on a mission to provide clinicians with tests and tools to preempt cancer through enhanced detection of precancerous cellular changes. The Suffern, NY-based company accomplishes this goal with WATS3, a diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods. MD+DI caught up with the company’s founder and CSO to discuss the evolution of the company and where it goes from here. MD+DI: Let’s talk a little bit about CDx Diagnostics as a company. What was the impetus behind it forming? What need were you attempting to meet? Talk about the journey you were on with the company and where it is today. Rutenberg: “The founding of CDx Diagnostics was based on an understanding that by adding AI to cytopathology we could enhance the detection of still-harmless but precancerous cells in time to prevent invasive cancer. Over 95% of cancers in adults are carcinomas, meaning that they arise from the epithelium, the 500µ thick layer of tissue that lines our organs.” “It takes several years for precancerous cells in the epithelium (“dysplasia”) to progress into invasive cancer and if these cells are found and removed or destroyed during that period, cancer can be prevented before it actua...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news